Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

425
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
425
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

554
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
554
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

557
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
557
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

618
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
618
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

474
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
474
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

720
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
720

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Retraction notice to 'Propranolol to decrease time to delivery: a meta-analysis of randomized controlled trials'. Retraction notice to AJOGMF Volume 6, Issue 10/ October 2024/ 101459.

American journal of obstetrics & gynecology MFM·2026
Same author

Association of Prepregnancy Obesity and Excessive Gestational Weight Gain with Perinatal Outcomes among Patients with Pregestational Diabetes.

American journal of perinatology·2026
Same author

Identification of de novo variants from parent-proband duos via long-read sequencing.

American journal of human genetics·2026
Same author

Acute Fatty Liver of Pregnancy and Fetal Fatty Acid Oxidation Disorders: A Systematic Review.

O&G open·2026
Same author

Hereditary Anemias as a Monogenic Etiology for Nonimmune Hydrops Fetalis.

Clinical therapeutics·2026
Same author

First-Trimester Machine Learning to Predict Preeclampsia in Normotensive Pregnancies by American Heart Association Guidelines.

American journal of perinatology·2026

相关实验视频

Updated: Jun 17, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.3K

普罗巴诺洛尔可以减少分娩的时间:随机对照试验的元分析.

Sonia Biswas1, Mariella Toro2, Rebecca Horgan3

  • 1Department of Obstetrics and Gynecology, Monmouth Medical Center, Long Branch, NJ (Biswas).

American journal of obstetrics & gynecology MFM
|August 8, 2024
PubMed
概括
此摘要是机器生成的。

在劳动诱导期间使用普罗普拉诺洛可显著缩短约91分钟的分娩时间. 然而,它并没有显著减少劳动增强的分娩时间,没有观察到增加的风险.

关键词:
增强 增强 增强 增强这是一种β-阻断剂.感应感应感应是一种感应感应.劳动力劳动力劳动力劳动力这种药物是propranolol.

更多相关视频

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

22.8K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.0K

相关实验视频

Last Updated: Jun 17, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.3K
Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

22.8K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.0K

科学领域:

  • 产科和妇科 产科和妇科
  • 药理学 药理学是指药理学的学科.
  • 临床试验 临床试验

背景情况:

  • 诱导分娩 (IOL) 和增加分娩是常见的产科干预措施.
  • 贝塔抑制剂 (如普拉诺洛尔) 在改变分娩时间方面的作用具有临床意义.
  • 关于普罗普拉诺洛尔对分娩时间的影响的证据需要合成.

研究的目的:

  • 为了评估普拉诺洛尔对在接受分娩诱导或增产的患者分娩时间的影响.
  • 综合来自随机对照试验 (RCT) 关于propranolol在分娩中的有效性和安全性的研究结果.

主要方法:

  • 在PubMed,Scopus,Cochrane图书馆,ClinicalTrials.gov和CINAHL的综合文献搜索,截至2023年12月.
  • 包括RCT比较propranolol与安慰剂或标准护理的诱导或增强.
  • 排除非随机试验,观察性研究和使用非标准对照组的研究.

主要成果:

  • 分析了9个涉及1,182名患者的RCT.
  • 普罗巴诺洛尔显著减少了在劳动诱导期间分娩的时间 (MD,-91.5分钟;95%CI -110.6至-72.4).
  • 在劳动增强期间没有观察到分娩时间的显著减少 (MD,-2.98分钟;95%CI -21.6至15.6).
  • 聚合分析显示,IOL和增强组合的平均减少时间为46.15分钟 (95% CI -59.48至-32.81).
  • 产后出血,输血,剖腹产或NICU入院的风险增加与使用普拉诺洛尔无关.

结论:

  • 兰醇的使用有效地缩短了约91分钟的分娩时间,当用于分娩诱导.
  • 当用于劳动增强时,甲醇不会显著减少分娩时间.
  • 在劳动诱导和增强期间使用普拉诺洛尔与增加的孕产妇或新生儿不良结果无关.